Full Breakdown
CDC6 Expression as a Prognostic Biomarker in Cancer
9/26/2025, 2:04:51 PM
Overview of CDC6 Expression Across Cancers
Recent studies have highlighted the significant upregulation of CDC6 expression across various cancer types, including bladder cancer (BLCA), breast cancer (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal cancer (ESCA), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), and several others. Analysis of the TCGA dataset using the TIMER 2.0 and GEPIA databases revealed a consistent pattern of elevated CDC6 levels in tumor tissues compared to normal tissues, suggesting its potential role in cancer progression and metastasis.
Correlation with Tumor Stages and Prognosis
Further investigations have established a correlation between CDC6 expression and tumor stages in multiple cancers, including ACC, BRCA, and LIHC. Survival analyses conducted using the Sangerbox platform indicated that higher CDC6 expression is associated with poorer overall survival (OS) and disease-specific survival (DSS) in malignancies such as glioblastoma multiforme (GBMLGG), KIRP, and LIHC. Conversely, elevated CDC6 levels appeared protective in certain contexts, such as in thymoma (THYM) and read-through (READ) cancers.
Immune Infiltration and Tumor Microenvironment
CDC6 expression has also been linked to immune cell infiltration within the tumor microenvironment. Analysis using the CIBERSORT algorithm revealed a positive correlation between CDC6 levels and the presence of various immune cells, including B cells, T cells, and macrophages. This suggests that CDC6 may influence tumor immunity, potentially affecting the efficacy of immunotherapies.
Associations with Immune Checkpoint Genes and Tumor Mutational Burden
The expression of CDC6 has been shown to correlate with immune checkpoint (ICP) genes, which are crucial for regulating immune responses in tumors. Elevated CDC6 levels were associated with increased tumor mutational burden (TMB) and microsatellite instability (MSI) in several cancer types, indicating its potential as a biomarker for predicting responses to immunotherapy.
Epigenetic Regulation and Genomic Alterations
Analysis of CDC6 promoter methylation across various cancers revealed significant hypermethylation in COAD, ESCA, and other malignancies, while hypomethylation was noted in BLCA and PRAD. Additionally, genomic alterations, particularly gene amplification, were prevalent in aggressive cancers such as esophageal adenocarcinoma and stomach adenocarcinoma, further underscoring the oncogenic potential of CDC6.
Conclusion
Collectively, these findings position CDC6 as a promising prognostic biomarker across multiple cancer types. Its expression levels not only correlate with tumor progression and patient outcomes but also interact with immune mechanisms, suggesting a multifaceted role in cancer biology. Future research may focus on leveraging CDC6 as a target for therapeutic interventions and improving patient stratification in cancer treatment.
Verbatim Quotes
- “In conclusion, our results demonstrate that CDC6 serves as a potential prognostic biomarker in multiple cancers, with its expression levels exhibiting distinct associations with patient outcomes depending on the tumor type.” — Research Team, BMC Cancer
- “These findings suggest that elevated CDC6 expression may serve as a novel predictive biomarker for immunotherapy efficacy in these specific cancer types, potentially reflecting enhanced tumor immunogenicity through its association with established markers of immunotherapy response.” — Research Team, BMC Cancer
Official Statements & Responses
The research findings indicate that CDC6 expression is significantly dysregulated across various cancers, reinforcing its potential as a biomarker for clinical applications. The correlation with immune cell infiltration and immune checkpoint genes further emphasizes the need for continued exploration of CDC6 in the context of cancer immunotherapy.
Conflicting Reports & Gaps
While the majority of studies support the upregulation of CDC6 in various cancers, discrepancies exist regarding its role as a protective factor in certain malignancies, such as THYM and READ. Further investigation is required to clarify these conflicting observations and to explore the underlying mechanisms of CDC6 in cancer progression and treatment response.
